Skip to main content
SpringerLink
Log in

Economic implications of OVA-301 trial in ovarian cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. incremental cost-effectiveness ratio

  2. National Health Service and Personal Social Services

Reference

  • Fisher M, et al. Cost-Effectiveness of Trabectedin Plus Pegylated Liposomal Doxorubicin for the Treatment of Women with Relapsed Platinum-Sensitive Ovarian Cancer in the UK: Analysis Based on the Final Survival Data of the OVA-301 Trial. Value in Health 16: 507-516, No. 4, Jun 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2013.01.011

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Economic implications of OVA-301 trial in ovarian cancer. PharmacoEcon Outcomes News 682, 4 (2013). https://doi.org/10.1007/s40274-013-0534-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0534-z

Search

Navigation